# Underactive thyroid on VEGFR-targeted tyrosine kinase inhibitors: thyroid tests and levothyroxine

Source: https://onco.cc/protocols/hypothyroidism-on-tyrosine-kinase-inhibitors/  
OnCo record `hypothyroidism-on-tyrosine-kinase-inhibitors` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Many targeted cancer tablets that block blood vessel growth, such as sunitinib, axitinib, lenvatinib and cabozantinib, can make the thyroid underactive. It causes tiredness, feeling cold, constipation and weight gain, which are easy to blame on the cancer. A blood test (TSH) before and during treatment finds it, and a daily levothyroxine tablet treats it. Your own team's plan comes first.

## Summary

VEGFR-targeted kinase inhibitors cause hypothyroidism, sometimes after a brief thyrotoxic phase, probably through loss of thyroid capillaries. Label rates: hypothyroidism in 19% on axitinib (TSH rising to 10 or more in 32% of those under 5 beforehand), thyroid dysfunction in 19% on cabozantinib, hypothyroidism in 21% to 24% on lenvatinib, 8% on tivozanib, 4% to 7% on pazopanib and 17% to 21% on fruquintinib (31.5% in the EU text, median onset 56 days). Reviews put it at 32% to 85% on sunitinib, with onset from 4 to 94 weeks. In people already taking levothyroxine, including after thyroidectomy, these medicines can raise the dose needed: on vandetanib 49% needed more against 17% on placebo.

Most labels ask for thyroid function before treatment and during it, and differ on how often: at least monthly for lenvatinib (US); every 3 months for sunitinib (EU); at baseline, 2 to 4 weeks, 8 to 12 weeks and then every 3 months for vandetanib; 'periodically' for axitinib and tivozanib; at baseline, during treatment and as clinically indicated for pazopanib; for cabozantinib (US), an assessment for signs before and during treatment with testing 'as clinically indicated'. The sorafenib US label asks for monthly TSH only in differentiated thyroid cancer, where it impairs TSH suppression; the regorafenib and fruquintinib US labels list hypothyroidism without a monitoring instruction, and the EU regorafenib text asks only for biochemical and metabolic monitoring in general. Two endocrine reviews give tighter schedules: TSH monthly for 4 months then every 2 to 3 months (Hamnvik 2011), or monthly for 6 months, on day 1 of the cycle for intermittent regimens, then every 2 to 3 months (French expert opinion 2018, abstract only).

Treatment: levothyroxine for a TSH above 10 mIU/L or a low free T4 (Hamnvik), or for symptomatic hypothyroidism or a TSH above 10 mIU/L (French opinion). They differ below that: Hamnvik finds a low-dose trial reasonable for a TSH of 5 to 10 because symptoms are hard to tell from those of cancer treatment; the French opinion treats only symptomatic hypothyroidism or a TSH above 10. The ATA guideline covers dosing: full or partial replacement titrated to TSH, rechecked 4 to 6 weeks after any change. Starting doses: 1.6 micrograms per kg a day is called reasonable without cardiac disease, and a lower dose such as 50 micrograms a day for the first few weeks in coronary artery disease (Hamnvik); NICE gives similar figures for primary hypothyroidism in general (see variants). The French opinion says the kinase inhibitor should not be stopped because of thyroid dysfunction, and no label read has a dose rule specific to it.

## Fields

- Kind: Protocol
- Last checked: 2026-11-17
- Also known as: TKI-induced hypothyroidism; sunitinib hypothyroidism; axitinib hypothyroidism; lenvatinib hypothyroidism; cabozantinib thyroid dysfunction; pazopanib hypothyroidism; thyroid monitoring on kinase inhibitors; TSH monitoring on anti-angiogenic tablets; levothyroxine on tyrosine kinase inhibitors

## Connected records

- protocols: [High blood pressure and protein in the urine on VEGF-pathway inhibitors: monitoring, treatment and when to pause the cancer medicine](https://onco.cc/protocols/hypertension-and-proteinuria-on-vegf-pathway-inhibitors/), [Thyroid inflammation and underactive thyroid from checkpoint inhibitors](https://onco.cc/protocols/irae-thyroid/)
- drugs: [Axitinib](https://onco.cc/drugs/axitinib/), [Cabozantinib](https://onco.cc/drugs/cabozantinib/), [Fruquintinib](https://onco.cc/drugs/fruquintinib/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/), [Levothyroxine](https://onco.cc/drugs/levothyroxine/), [Pazopanib](https://onco.cc/drugs/pazopanib/), [Sorafenib](https://onco.cc/drugs/sorafenib/), [Sunitinib](https://onco.cc/drugs/sunitinib/), [Tivozanib](https://onco.cc/drugs/tivozanib/), [Vandetanib](https://onco.cc/drugs/vandetanib/)
- targets: [VEGF / VEGFR](https://onco.cc/targets/vegf/)

---
JSON: https://onco.cc/api/v1/entities/hypothyroidism-on-tyrosine-kinase-inhibitors.json